Skip to main content
. 2017 Oct 3;9(2):360–365. doi: 10.1111/jdi.12739

Figure 1.

Figure 1

Serial changes in low‐density lipoprotein cholesterol (LDL‐C). (a, d) The anagliptin (ANA) group and (b, e) the alogliptin (ALO) group. (d, e) Data of patients with LDL‐C ≥ 140 mg/dL at baseline. (c) Data of all patients and (f) data of patients with LDL‐C ≥ 140 mg/dL at baseline. *P < 0.05, vs baseline, by anova.